In multiple myeloma, a high-dose conditioning treatment prior to stem cell transplant
Prescribing Information Important Safety Information

    EVOMELA Bioequivalence

    EVOMELA—Bioequivalent to conventional IV melphalan based on Phase IIa cross-over study2

    EVOMELA was FDA approved based, in part, on its bioequivalence to Alkeran via the 505(b)(2) New Drug Application regulatory pathway.1-4

    EVOMELA has a PK profile comparable to conventional IV melphalan2

    Mean melphalan plasma concentration-time profiles following infusion of EVOMELA and Alkeran. Alkeran (melphalan) is a registered trademark of GlaxoSmithKline, distributed by ApoPharma USA Inc.

    Selected Important Safety Information

    Warnings and Precautions

    Bone Marrow Suppression:
    • For patients receiving EVOMELA as part of a conditioning regimen, myeloablation occurs in all patients. Do not begin the conditioning regimen if a stem cell product is not available for rescue. Monitor complete blood counts, provide supportive care for infections, anemia, and thrombocytopenia until there is adequate hematopoietic recovery.
    References
    1. EVOMELA Prescribing Information. Acrotech Biopharma, LLC. 
    2. Aljitawi OS, Ganguly S, Abhyankar SH, et al. Phase IIa cross-over study of propylene glycol-free melphalan (LGD-353) and alkeran in multiple myeloma autologous transplantation. Bone Marrow Transplant. 2014;49(8):1042-1045.
    3. Hari P. Aijitawi OS. Arce-Lara C. et al. A phase IIb. multicenter. open-label. safety. and efficacy study of high-dose. propylene glycol-free melphalan hydrochloride for injection (EVOMELA) for myeloablative conditioning in multiple myeloma patients undergoing autologous transplantation. Biol Blood Marrow Transplant. 2015:21(12):2100-2105.
    4. FDA. Center for Drug Evaluation and Research. EVOMELA Drug Application. 2016.
    Important Safety Information
    Click to Hide Advanced Floating Content
    Important Safety Information
    Warnings and Precautions

    Bone Marrow Suppression: For patients receiving EVOMELA as part of a conditioning regimen, myeloablation occurs in all patients. Do not begin the conditioning regimen if a stem cell product is not available for rescue. Monitor complete blood counts, provide supportive care for infections, anemia and thrombocytopenia until there is adequate hematopoietic recovery.

    See More